Atherosclerosis, Inflammation
Conditions
Keywords
DOTATATE, Ziltivekimab, Inflammation, Monocytes, CCTA, PET/CT
Brief summary
The goal of this randomized, double blind, placebo controlled trial is to study whether ziltivekimab therapy reduces arterial wall inflammation as assessed by imaging, and reduces the systemic inflammatory tone as assessed by circulating monocytes, inflammatory biomarkers and proteomics.
Detailed description
Considering that ziltivekimab is currently undergoing a phase 3 CVOT trial, it is of great importance to elucidate its mechanistic effects. The objective of this study is to research whether ziltivekimab therapy for 20 weeks reduces arterial wall inflammation, as assessed by state-of-the-art imaging modalities, and reduces systemic inflammatory tone, as assessed by in depth phenotyping of circulating monocytes, inflammatory biomarkers and proteomics. The imaging modalities used in this study are 68Ga-DOTATATE PET/CT and CCTA. This study is designed as a single center, randomized, double-blinded, placebo-controlled intervention study in 40 atherosclerotic patients of 50 years and older with hsCRP levels of 2 mg/L and above.
Interventions
DRUGZiltivekimab
Monoclonal antibody targeting IL-6
DRUGPlacebo
Placebo
Sponsors
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
After informed consent has been obtained, patients will be randomized via computer randomization to either 15 mg ziltivekimab (n=20) or placebo (n=20). On the eCRFs or other documents subjects will be identified by subject ID and randomization number only.
Intervention model description
randomized, double blind, placebo-controlled trial
Eligibility
Sex/Gender
ALL
Age
50 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Aged 50 years and older. * Multi-vessel coronary artery disease (defined as CAD-RADS ≥2). * Serum hsCRP level ≥2 mg/L.
Exclusion criteria
* Coronary stents in situ. * Chronic or recent (\<1 month) (serious) infections and/or clinical signs of acute (serious) infection. * History of severe auto-immune diseases, or other (severe) (recurrent or chronic) inflammatory disorders. * Use of preventive systemic antibiotics (antibiotics used to treat latent tuberculosis are exempted). * Stable lipid lowering treatment for less than 4 weeks, including statins, ezetimibe and PCSK9 inhibition. * Untreated latent tuberculosis, active hepatitis B (positive HBsAg and/or positive anti-HBc with detectable HBV DNA) or C, human immunodeficiency virus (HIV) not on stable antiretroviral regimen * Uncontrolled diabetes (HbA1c \>90 mmol/mol). * Renal insufficiency, defined as eGFR \<45 ml/min/1.73 m2. * Platelet count \<120,000 and \>450,000 /mm3. * Elevated liver enzymes (\>3 ULN of liver transaminases), acute liver failure or known (severe) liver disease. * Premenopausal women not using birth-control. * History of gastrointestinal perforation, active diverticulitis (within 5 years) or active inflammatory bowel disease (within 12 months). * Uncontrolled hypertension (systolic \>180 mmHg; diastolic \>110 mmHg). * Diagnosis of (active) malignancy in last 5 years. * Standard contra-indications to 68Ga-DOTATATE PET, and CT based on physician's experience and current practices. * Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| TBRmax coronary arteries | 5.5 months | mean percentage change in coronary arteries target to background ratio (TBRmax) |
| monocyte activation marker protein expression | 5.5 months | The impact of ziltivekimab on a mass cytometry monocyte phenotype panel; expression markers such as CD14 and CD16. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| delta PCAT | 5.5 months | Difference in PCAT (CCTA derived) after ziltivekimab treatment. |
| Correlation delta TBRmax and CCTA derived plaque characteristics | 5.5 months | Correlation between changes in coronary 68Ga-DOTATATE uptake and anatomical plaque changes on CCTA. |
| delta SUVmax bone marrow | 5.5 months | Difference in 68Ga-DOTATATE SUVmax of bone marrow after treatment. |
| delta TBRmax ascending aorta | 5.5 months | Difference in 68Ga-DOTATATE TBRmax of ascending aorta after treatment |
| changes monocyte phenotype | 5.5 months | The impact of ziltivekimab on monocyte phenotype in transendothelial migration (TEM) capacity and transcriptome profile. |
| changes in hsCRP | 5.5 months | hsCRP (high-sensitivity C-reactive protein): mg/L |
| changes plasma cytokine and chemokine levels (pg/mL) | 5.5 months | TNF-α (Tumor Necrosis Factor alpha): pg/mL IL-8 (Interleukin-8): pg/mL MCP-1 (Monocyte Chemoattractant Protein-1): pg/mL |
| changes plasma cytokine and chemokine levels (ng/mL) | 5.5 months | sICAM (soluble Intercellular Adhesion Molecule): ng/mL sVCAM (soluble Vascular Cell Adhesion Molecule): ng/mL |
Countries
Netherlands
Contacts
PRINCIPAL_INVESTIGATORE.S.G. Stroes, Prof.dr.
Amsterdam UMC
Outcome results
None listed